Table 2.
Changes of hormone levels in prostate cancer patients treated GnRH antagonist
| Pre | 1 w | 2 w | 1 mo | 3 mo | 6 mo | 12 mo | Statistics | |
|---|---|---|---|---|---|---|---|---|
| T | p < 0.05 | |||||||
| Measurement, ng/dL percentile change |
376.66 ± 161.71 | 19.4 ± 9.11†
−94.8% (n = 39) |
11.8 ± 7.13†
−96.7% (n = 36) |
10.23 ± 5.09 −97.3% |
10.09 ± 3.98 −97.3% |
10.49 ± 4.52 −97.2% |
10.81 ± 5.36 −97.1% |
Pre vs 1 w, 2 w, 1 mo, 3 mo, 6 mo, 12 mo |
| DHT | p < 0.05 | |||||||
| Measurement, pg/mL percentile change |
442.76 ± 256.68 | 29.95 ± 15.89 −93.2% |
27.09 ± 15.28 −93.9% |
25.30 ± 14.48 −94.3% |
24.12 ± 14.01 −94.6% |
Pre vs 1 mo, 3 mo, 6 mo, 12 mo | ||
| E2 | p < 0.05 | |||||||
| Measurement, pg/mL percentile change |
23.58 ± 12.81 | 3.56 ± 2.58 −84.9% |
3.25 ± 2.21 −86.2% |
3.32 ± 2.01 −85.9% |
3.46 ± 2.37 −85.3% |
Pre vs 1 mo, 3 mo, 6 mo, 12 mo | ||
| DHEA-S | p < 0.05 | |||||||
| Measurement, μg/dL percentile change |
125.47 ± 62.48 | 104.38 ± 56.03 −16.8% |
103.7 ± 52.52 −17.3% |
104.17 ± 57.03 −17.0% |
95.47 ± 58.23 −23.9% |
Pre vs 1 mo, 3 mo, 6 mo, 12 mo | ||
| DHEA | p < 0.05 | |||||||
| Measurement, ng/mL percentile change |
2.50 ± 1.46 | 2.19 ± 1.52 −12.0% |
2.27 ± 1.45 −8.7% |
2.23 ± 1.57 −10.8% |
2.11 ± 1.69 −15.4% |
Pre vs 12 mo | ||
| A-dione | p < 0.05 | |||||||
| Measurement, ng/mL percentile change |
0.715 ± 0.348 | 0.458 ± 0.278 −35.5% |
0.472 ± 0.231 −33.9% |
0.448 ± 0.230 −37.4% |
0.426 ± 0.220 −40.5% |
Pre vs 1 mo, 3 mo, 6 mo, 12 mo | ||
| LH | p < 0.05 | |||||||
| Measurement, mIU/mL percentile change |
7.20 ± 7.31 | 0.285 ± 0.385 −96.0% |
0.255 ± 0.306 −96.5% |
0.303 ± 0.355 −95.8% |
0.453 ± 0.479 −93.7% |
Pre vs 1 mo, 3 mo, 6 mo, 12 mo | ||
| FSH | p < 0.05 | |||||||
| Measurement, mIU/mL percentile change |
14.56 ± 14.47 | 0.889 ± 1.100 −93.9% |
0.993 ± 0.100 −93.2% |
1.224 ± 1.135 −91.6% |
1.83 ± 1.424 −87.4% |
Pre vs 1 mo, 3 mo, 6 mo, 12 mo |
Abbreviations: T, Testosterone, DHT dihydrotestosterone, E 2 Estradiol, DHEA dehydroepiandrosterone, DHEA-S Dehydroepiandrosterone-sulfate, A-dione androstenedione, LH Luteinizing hormone, FSH Follicle Stimulating Hormone, Pre pretreatment, 1,2 w 1,2 weeks after initiation of GnRH antagonist treatment, 1,3,6,12 mo, 1,3,6,12 months after initiation of GnRH antagonist treatment
Percentile change indicates changes in comparison with pretreatment levels. Values are expressed as mean ± SD
†: Data of testosterone after 1 week (n = 39) and 2 weeks (n = 36) were measured by the ECLIA, and all other data were measured by LC-MS/MS